Advertisement
Screener

NRX Pharmaceuticals, Inc. (NRXP) Convertible Debt, Current

2.8 / 5 stars · 68/120 Roast Me

NRX Pharmaceuticals, Inc. Convertible Debt, Current

NRX Pharmaceuticals, Inc. (NRXP) had Convertible Debt, Current of $7.65 million as of 2024-06-30, per its 10-Q filed 2024-08-14.

Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities

us-gaap:ConvertibleDebtCurrent · last filed 2024-08-14

  • 2024-06-30: Convertible Debt, Current $7.65M.
  • 2023-06-30: Convertible Debt, Current $12.69M.
Period endConvertible Debt, Current
2024-06-30$7.65M
10-Q · filed 2024-08-14
2023-06-30$12.69M
10-Q · filed 2024-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
MEDICINOVA INC (MNOV)United States$0.130B-6.04
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95